Sadiq Al-Nakeeb, MD
Pulmonary Disease · Naples, FLNPI 1073562450
Payments from drug & device makers
Across 456 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- GSK$1K
- Inspire Medical Systems, Inc.$1K
- Boehringer Ingelheim$720
- Regeneron Healthcare Solutions, Inc.$526
- plus $5K from 31 others
What the payments were for
- Travel & lodging$7726%
- Food & beverage$11,24993%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 90 | $1,863 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $1,420 |
| GSK | 64 | $1,375 |
| Inspire Medical Systems, Inc. | 9 | $1,311 |
| Boehringer Ingelheim | 30 | $720 |
| Regeneron Healthcare Solutions, Inc. | 16 | $526 |
| Insmed, Inc. | 21 | $522 |
| Grifols USA, LLC | 19 | $426 |
| Sanofi | 12 | $390 |
| Actelion Pharmaceuticals US, Inc. | 13 | $369 |
| United Therapeutics Corporation | 13 | $334 |
| Philips North America LLC | 12 | $257 |
| Merck | 8 | $247 |
| Viatris Specialty LLC | 7 | $214 |
| Mylan Specialty L.p. | 10 | $206 |
| Verona Pharma, Inc. | 11 | $201 |
| Electromed, Inc. | 9 | $191 |
| Resmed Corp | 6 | $179 |
| Bayer | 9 | $173 |
| Axsome Therapeutics, Inc. | 7 | $163 |
| Amgen | 5 | $124 |
| Intuitive Surgical | 1 | $121 |
| Noctrix Health, Inc. | 1 | $121 |
| Jazz Pharmaceuticals Inc. | 5 | $114 |
| Johnson & Johnson | 4 | $81 |
| Medtronic | 1 | $80 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Advanced Respiratory, Inc | 2 | $55 |
| Baxter Healthcare | 2 | $42 |
| Genentech USA, Inc. | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Vapotherm Inc | 1 | $38 |
| Inogen, Inc. | 2 | $32 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| Covis Pharma GmbH | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$1,009
- TRELEGY ELLIPTA$237
- BREZTRI$205
- TEZSPIRE$205
- FASENRA$205
- AIRSUPRA$205
- Inspire$141
- Da Vinci Surgical System$121
- NIDRA$121
How this compares
$12,111 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $278,633 |
| OfevNintedanib Esylate | 20 | $272,523 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 152 | $123,932 |
| Breo ElliptaFluticasone/Vilanterol | 182 | $105,555 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $96,105 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $77,677 |
| Spiriva RespimatTiotropium Bromide | 71 | $63,235 |
| Incruse ElliptaUmeclidinium Bromide | 85 | $44,589 |
| Spiriva HandihalerTiotropium Bromide | 22 | $22,153 |
| XareltoRivaroxaban | 20 | $21,503 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $12,866 |
| Arnuity ElliptaFluticasone Furoate | 34 | $10,592 |
| DuleraMometasone/Formoterol | 11 | $10,317 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $6,232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $6,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,375 | $563,301720 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $720 | $413,436181 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,863 | $108,971143 claims |
| Johnson & JohnsonXarelto | $81 | $21,50320 claims |
| MerckDulera | $247 | $10,31711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Naples
- Lisette Delgado SanchezNaples$1.6M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.